Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : DD'S Cellar Dweller Stock Watch -- Ignore unavailable to you. Want to Upgrade?

To: John R Resseger who wrote (375)	5/31/1999 11:48:00 AM
From: John R Resseger	Respond to of 598

Antex uses its NST platform technology to develop several types of products for infectious diseases. The first products developed included novel subunit and inactivated whole cell vaccines. AntexPharma, a wholly owned subsidiary of AntexBiologics, has discovered that NST-grown bacteria have in vitro sensitivities to antibiotics more closely related to the therapeutic indexes seen in people. Antex has developed a line of screening assays using these NST bacteria to evaluate novel antibiotics. In addition, by making novel structural analogs of identified natural chemicals, Antex has discovered "modulators," compounds that inhibit the growth or virulence of these bacteria. These compounds may be useful as new types of therapeutics to treat antibiotic resistant bacteria, such as vancomycin resistant Enterococci and methicillin resistant Staphylococcus. . Antex's products and technologies are now covered by 22 U.S. patents with many more patents worldwide Some of these patents seem to cover pretty basic stuff. One of those Multibillion Drug companies might wake up and pay $10 a share for this stuff. Given